• 1

    Neuman KC, Chadd EH, Liou GF, et al: Characterization of photodamage to Escherichia coli in optical traps. .Bio-phys J 77::2856. ,1999. .

    • Search Google Scholar
    • Export Citation
  • 2

    Bornstein E: A review of current research in light-based technologies for treatment of podiatric infectious disease states. .JAPMA 99::348. ,2009. .

    • Search Google Scholar
    • Export Citation
  • 3

    Bornstein ES, Robbins AH, Michelon M, et al: “Photo-Inactivation of Fungal Pathogens That Cause Onychomycosis In Vitro and In Vivo with the Noveon® Dual Wavelength Laser System,” in Proceedings of the 9th Annual New Cardiovascular Horizons, New Orleans 2008, September 10–13, 2008, p 72, New Cardiovascular Horizons, Lafayette, LA. ,2008. . Abstract 70.

  • 4

    Bornstein ES, Hermans W, Gridley S: Near infrared photo-inactivation of bacteria and fungi at physiologic temperatures. .Photochem Photobiol 85::1364. ,2009. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Venugopalan V, Nishioka NS, Mikic BB: The thermodynamic response of soft biological tissues to pulsed infrared-laser irradiation. .Biophysical J 70::2981. ,1996. .

    • Search Google Scholar
    • Export Citation
  • 6

    Matsumu Y, Ananthaswamy HN: Toxic effects of ultraviolet radiation on the skin. .Toxicol Appl Pharmacol 195::298. ,2004. .

  • 7

    Watanabe D, Kawamura C, Masuda Y, et al: Successful treatment of toenail onychomycosis with photodynamic therapy. .Arch Dermatol 144::19. ,2008. .

  • 8

    Piraccini BM, Rech G, Tosti A: Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. .J Am Acad Dermatol 59::S75. ,2008. .

  • 9

    Donnelly RF, McCarron PA, Lightowler JM, et al: Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. .J Control Release 103::381. ,2005. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Jobsis-vanderVliet FF, Jobsis PD: Biochemical and physiological basis of medical near-infrared spectroscopy. .J Biomed Optics 4::397. ,1999. .

    • Search Google Scholar
    • Export Citation
  • 11

    Food and Drug Administration. Significant risk and non-significant risk medical device studies: information sheet guidance for IRBs, clinical investigators, and sponsors. Available at: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/UCM118082.pdf. Accessed March 10. ,2010. .

  • 12

    Lamisil AT [package insert], Novartis Pharmaceuticals, East Hanover, NJ..

  • 13

    Gupta M, Sharma NL, Kanga AK, et al: Onychomycosis: clinico-mycologic study of 130 patients from Himachal Pradesh, India. .Indian J Dermatol Venereol Leprol 73::389. ,2007. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Edwards LF, Schott RG: The daily rate of growth of toenails. .Ohio J Sci 37::91. ,1937. .

  • 15

    Gupta M, Tu L: Onychomycosis therapies: strategies to improve efficacy. .Dermatol Clin 24::381. ,2006. .

  • 16

    Lecha M, Feuilhade De Chauvin M, Di Chiacchio N, et al: Treatment options: development of consensus guidelines. .J Eur Acad Dermatol Venereol .19: (suppl 1):25. ,2005. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Joseph WS: Why it’s essential to treat onychomycosis as an infection. .Podiatry Today 17. (suppl 6a):2004. .

  • 18

    Lamisil (terbinafine hydrochloride) tablets prescribing information. Novartis Website. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/Lamisil_tablets.pdf. Accessed March 18. ,2010. .

  • 19

    Kim M-S, Kim YK, Cho KH, et al: Infrared exposure induces and angiogenic switch in human skin that is partially mediated by heat. .Br J Dermatol 155::1131. ,2006. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Reisberger EM, Abels C, Landthaler MI, et al: Histopathological diagnosis of onychomycosis by periodic acid-Schiff-stained nail clippings. .Br J Dermatol 148::749. ,2003. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    “Broad-spectrum Ultraviolet (UV) Radiation and UVA, and UVB, and UVC,” in Report on Carcinogens, 11th Ed, US Department of Health and Human Services, Public Health Service, National Toxicology Program. ,2006. .

  • 22

    Vural E, Winfield HL, Shingleton AW, et al: The effects of laser irradiation on Trichophyton rubrum growth. .Lasers Med Sci 23::349. ,2008. .

Treatment of Mild, Moderate, and Severe Onychomycosis Using 870- and 930-nm Light Exposure

View More View Less
  • 1 Division of Podiatric Surgery, Beth Israel Deaconess Medical Center, Boston, MA.
  • | 2 Nomir Medical Technologies Inc, Waltham, MA.
  • | 3 Southboro Medical Group, Southboro, MA.
  • | 4 Private practice, Revere, MA.
Restricted access

Background: The Noveon is a unique dual-wavelength near-infrared diode laser used to treat onychomycosis. The device operates at physiologic temperatures that are thermally safe for human tissue. It uses only 870- and 930-nm near-infrared light, wavelengths that have unique photolethal effects on fungal pathogens. These wavelengths lack the teratogenic danger presented by ultraviolet light and the photoablation toxic plume associated with pulsed Nd:YAG lasers.

Methods: In this randomized controlled study, treatments followed a predefined protocol and laser parameters and occurred on days 1, 14, 42, and 120. Toes were cultured and evaluated, and measurements were taken from standardized photographs obtained periodically during the 180 day follow-up period.

Results: We treated mycologically confirmed onychomycosis in 26 eligible toes (ten mild, seven moderate, and nine severe). All of the patients were followed-up for 180 days. An independent expert panel, blinded regarding treatment versus control, found that at 180 days, 85% of the eligible treated toenails were improved by clear nail linear extent (P = .0015); 65% showed at least 3 mm and 26% showed at least 4 mm of clear nail growth. Of the 16 toes with moderate to severe involvement, ten (63%) improved, as shown by clear nail growth of at least 3 mm (P = .0112). Simultaneous negative culture and periodic acid–Schiff was noted in 30% at 180 days.

Conclusions: These results indicate a role for this laser in the treatment of onychomycosis, regardless of degree of severity. Ease of delivery and the lack of a need to monitor blood chemistry are attractive attributes. (J Am Podiatr Med Assoc 100(3): 166–177, 2010)

Corresponding author: Alan H. Robbins, MD, Nomir Medical Technologies Inc, 307 Waverley Oaks Rd, Ste 109, Waltham, MA 02452. (E-mail: cfolster@nomirmedical.com)